SCHEDULE: FMR LLC Discloses 8.8% Stake in NewAmsterdam Pharma

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 8.8% in NewAmsterdam Pharma Company NV as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson, through various entities, collectively beneficially own 10,339,663 shares of NewAmsterdam Pharma Company NV's common stock.
• This represents 8.8% of the class of securities outstanding as of June 30, 2026.
• The filing is an amendment (Amendment No. 2) to a Schedule 13G, indicating a change or update to their previous filing.
• FMR LLC is classified as a 'HC' (likely Holding Company or similar institutional classification) and Abigail P. Johnson is classified as 'IN' (likely Investor or Individual).
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, indicating a significant but stable institutional holding without immediate aggressive action.

Positives

• Significant institutional ownership by FMR LLC and Abigail P. Johnson, indicating confidence in the company.
• The reported stake of 8.8% is substantial and suggests a long-term investment perspective.
• Confirmation that the holdings are for ordinary course of business, not for control, which can be reassuring to other investors.

Negatives

• The filing does not provide specific details on the acquisition cost or strategy behind the increased stake.
• No forward-looking statements or specific performance targets are mentioned in this filing.

Risks

• Potential for future changes in FMR LLC's stake, which could impact share price if significant buying or selling occurs.
• Dependence on the investment decisions of large institutional holders like FMR LLC.

Future Outlook

The filing itself does not contain forward-looking statements or specific guidance regarding the company's future performance. It primarily reports on current beneficial ownership.

Management Comments

• "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters')."
• "No one other person's interest in the COMMON STOCK of NEWAMSTERDAM PHARMA COMPANY NV is more than five percent of the total outstanding COMMON STOCK."
• "The undersigned persons, on August 5, 2026, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of NEWAMSTERDAM PHARMA COMPANY NV at June 30, 2026."

Industry Context

StockSavvy.ai notes that significant institutional filings like this Schedule 13G are common in the pharmaceutical sector, reflecting active portfolio management by large investment firms. The 8.8% stake by FMR LLC suggests a notable position within their broader investment strategy.

Stakeholder Impact

• Shareholders: May view the significant stake by FMR LLC as a positive indicator of institutional confidence, potentially stabilizing or increasing share value. However, future trading activity by FMR LLC could also impact price.
• Management: The filing confirms that the ownership is not for control, which may reduce immediate pressure for management changes or strategic shifts driven by this specific holder.
• Creditors: Indirectly impacted by the company's perceived stability and investor confidence, which a large institutional holding can support.

Next Steps

• Monitor future filings from FMR LLC and Abigail P. Johnson for any changes in their beneficial ownership.
• Observe NewAmsterdam Pharma Company NV's subsequent financial reports and strategic announcements for performance indicators.

Key Dates

Keywords

NewAmsterdam Pharma, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management